The AMR Action Fund was credited with "[bringing] together drugmakers and NGOs with the aim of launching two to four new antimicrobials within the next decade.”
The guide arrives as the growing risks of AMR are rippling through industries and investment portfolios. It reveals AMR could translate to $1 trillion in additional healthcare costs and shrink global economic output by 3.8% annually by 2050. While clinical development of products for priority pathogens included 97 products (57 antibiotics and 40 nontraditional antibacterials) as of December 2023, the current clinical pipeline and the antibiotics that have been recently approved are insufficient to address the growing challenge of AMR.